ALKS Insider Trading
SEC Form 4 transaction history for ALKS. Filings have up to a 2 business day reporting delay.
Insiders at ALKS reported 10 open-market sells worth $4.6M in the last 90 days, with no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification, and estate reasons all the time. Latest filing: snyderman nancy lynn MD on 2026-08-03.
Transaction History
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-03 | snyderman nancy lynn MD | - | Option exercise | 27.9K | $46.72 | $1.3M |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9.0K | $48.58 | $437K |
| 2026-08-03 | snyderman nancy lynn MD | - | Option exercise | 16.5K | $46.72 | $772K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 4.9K | $24.59 | $120K |
| 2026-08-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.0K | $48.58 | $99K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 104 | $19.34 | $2K |
| 2026-08-03 | snyderman nancy lynn MD | - | Sell | 44.5K | $50.35 | $2.2M |
| 2026-07-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.0K | $54.03 | $110K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 8.3K | $51.46 | $427K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 700 | $52.13 | $36K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2026-06-12 | Wright Christopher I | - | Sell | 2.0K | $45.10 | $90K |
| 2026-06-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.0K | $43.05 | $88K |
| 2026-06-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2026-06-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9.0K | $41.67 | $375K |
| 2026-05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell | 16.2K | $42.36 | $687K |
| 2026-05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise | 3.4K | $20.03 | $68K |
| 2026-05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise | 12.8K | $19.34 | $248K |
| 2026-05-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.0K | $33.20 | $68K |
| 2026-05-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2026-05-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9.0K | $33.40 | $301K |
| 2026-04-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.0K | $34.57 | $70K |
| 2026-04-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2026-04-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9.0K | $35.51 | $320K |
| 2026-03-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.0K | $29.76 | $61K |
| 2026-03-02 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell | 6.9K | $29.29 | $202K |
| 2026-03-02 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sell | 6.0K | $30.00 | $180K |
| 2026-03-02 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9.0K | $29.72 | $267K |
| 2026-03-02 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2026-03-02 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.0K | $29.29 | $60K |
| 2026-02-02 | Cooke Shane | - | Option exercise | 61.2K | $31.64 | $1.9M |
| 2026-02-02 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2026-02-02 | Cooke Shane | - | Sell | 32.1K | $34.78 | $1.1M |
| 2026-02-02 | Cooke Shane | - | Sell | 29.1K | $34.34 | $999K |
| 2026-02-02 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 5.0K | $34.24 | $171K |
| 2026-02-02 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 4.0K | $33.54 | $134K |
| 2026-01-08 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 5.0K | $30.00 | $150K |
| 2026-01-08 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2026-01-02 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 4.0K | $28.00 | $112K |
| 2025-12-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 3.7K | $30.00 | $112K |
| 2025-12-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 3.7K | $19.34 | $72K |
| 2025-12-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 4.0K | $29.30 | $117K |
| 2025-11-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9.0K | $30.38 | $273K |
| 2025-11-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2025-10-15 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5.0K | $19.34 | $97K |
| 2025-10-15 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9.0K | $31.53 | $284K |
Understanding
Interpreting ALKS insider filings
Officers, directors, and 10% owners of ALKS must report every trade in their own stock to the SEC within two business days on Form 4. We parse each filing as it lands on EDGAR, so this page is the same primary-source record professionals read, minus the paywall.
The asymmetry that makes this data useful: insiders sell for dozens of innocent reasons (taxes, diversification, a house), but they voluntarily buy on the open market for exactly one reason. That is why buys are headlined and one-off sells deserve little weight.
The strongest historical pattern is the cluster: several different insiders buying within days of each other. A lone director's small buy is noise; the CFO and two directors buying the same week is a documented anomaly worth your attention.
Frequently Asked Questions
Who files Form 4 for ALKS?
What do the transaction types mean?
How fresh is this data?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.